Zurletrectinib is a brain-penetrant, orally active TRK inhibitor (TRKA IC50 = 0.81 nM, TRKB IC50 = 0.145 nM, TRKC IC50 = 0.184 nM). Zurletrectinib exhibits stronger activity as a consequence of its augmented binding affinity for TRK kinases. Zurletrectinib exhibits higher activity against most TRK inhibitor resistance mutations (13 out of 18 mutations). Zurletrectinib can be used for the study of glioma[1].
Molekulargewicht:
415.40
Reinheit:
99.32
CAS Nummer:
[2403703-30-8]
Formel:
C19H19F2N7O2
Target-Kategorie:
c-Met/HGFR,Trk Receptor
Anwendungsbeschreibung:
MCE Product type: Reference compound1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
